-+ 0.00%
-+ 0.00%
-+ 0.00%

ITERION THERAPEUTICS ANNOUNCES PROMISING PHASE 1B DATA FOR TEGAVIVINT IN COMBINATION WITH OSIMERTINIB IN FIRST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Reuters·09/22/2026 12:09:47

Please log in to view news